Tackling Osimertinib Resistance in EGFR-Mutant Non–Small Cell Lung Cancer
JB Blaquier, S Ortiz-Cuaran, B Ricciuti, L Mezquita… - Clinical Cancer …, 2023 - AACR
The current landscape of targeted therapies directed against oncogenic driver alterations in
non–small cell lung cancer (NSCLC) is expanding. Patients with EGFR-mutant NSCLC can …
non–small cell lung cancer (NSCLC) is expanding. Patients with EGFR-mutant NSCLC can …
Decoding oncofusions: unveiling mechanisms, clinical impact, and prospects for personalized cancer therapies
K Salokas, G Dashi, M Varjosalo - Cancers, 2023 - mdpi.com
Simple Summary Oncofusions, or cancer-associated fusion mutations, are driving forces in
cancer development. Advanced sequencing technologies have revolutionized their …
cancer development. Advanced sequencing technologies have revolutionized their …
Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers
TC Cheong, A Jang, Q Wang, GC Leonardi… - Nature …, 2024 - nature.com
Tyrosine kinase (TK) fusions are frequently found in cancers, either as initiating events or as
a mechanism of resistance to targeted therapy. Partner genes and exons in most TK fusions …
a mechanism of resistance to targeted therapy. Partner genes and exons in most TK fusions …
New Treatment Options for Patients With Oncogene-Addicted Non–Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors
Druggable oncogene-driven non–small cell lung cancer has led to innovative systemic
treatment options, improving patients' outcome. This benefit is not only achieved in the …
treatment options, improving patients' outcome. This benefit is not only achieved in the …
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor …
The year 2024 is the 20th anniversary of the discovery of activating epidermal growth factor
receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). Since then, tremendous …
receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). Since then, tremendous …
Applications and advancements of CRISPR-Cas in the treatment of lung cancer
P Lei, Y Ju, F Peng, J Luo - Frontiers in Cell and Developmental …, 2023 - frontiersin.org
Lung cancer is one of the most malignant diseases and a major contributor to cancer-related
deaths worldwide due to the deficiency of early diagnosis and effective therapy that are of …
deaths worldwide due to the deficiency of early diagnosis and effective therapy that are of …
Identification of a novel fusion gene NLRC3-NLRP12 in miiuy croaker (Miichthys miiuy)
G Liu, S Xin, S Geng, W Zheng, T Xu, Y Sun - Fish & Shellfish Immunology, 2023 - Elsevier
Fusion gene is a new gene formed by the fusion of all or part of the sequences of two genes,
it is caused by chromosome translocation, middle deletion or chromosome inversion …
it is caused by chromosome translocation, middle deletion or chromosome inversion …
Combined Dacomitinib and Selpercatinib Treatment for a Patient with EGFR-Mutant Non-Small Cell Lung Cancer and Acquired CCDC6-RET Fusion
CY Liu, CH Liu - OncoTargets and Therapy, 2024 - Taylor & Francis
RET rearrangements are recognized drivers in lung cancer, representing a small subset (1–
2%) of non-small cell lung cancer (NSCLC). Additionally, RET fusions also serve as a rare …
2%) of non-small cell lung cancer (NSCLC). Additionally, RET fusions also serve as a rare …
Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC
U Malapelle, F Tabbò, LA Muscarella - Frontiers in Oncology, 2023 - frontiersin.org
Starting from the Epidermal Growth Factor Receptor (EGFR)(1) and Anaplastic Lymphoma
Kinase (ALK)(2), and continuing with the identification of other well-known driver genes for …
Kinase (ALK)(2), and continuing with the identification of other well-known driver genes for …
Impact of smoking in resected lung cancer depends on epidermal growth factor receptor mutation
K Sekihara, A Kawase, Y Matsubayashi… - Interdisciplinary …, 2024 - academic.oup.com
OBJECTIVES Smokers comprise majority of surgical patients with primary lung cancer.
Epidermal growth factor receptor (EGFR) mutation-negative status impacts the treatment of …
Epidermal growth factor receptor (EGFR) mutation-negative status impacts the treatment of …